News
06-14-2010, 06:11 AM
Telormedix, a clinical stage biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases, today announced the start of a Phase I/II clinical study of TMX-101 for the treatment of Non-Muscle Invasive Bladder Cancer. TMX-101 is an immunotherapeutic compound and Telormedix has already recruited the first patients for this clinical study.
More... (http://www.news-medical.net/news/20100614/Telormedix-initiates-Phase-III-clinical-study-of-TMX-101-for-treating-NMIBC.aspx)
More... (http://www.news-medical.net/news/20100614/Telormedix-initiates-Phase-III-clinical-study-of-TMX-101-for-treating-NMIBC.aspx)